Baker & McKenzie Represents Elsevier in Acquisition of Ariadne Genomics
13 December 2011
New York, USA, December 13, 2011 – Baker & McKenzie is representing Elsevier, a world-leading provider of scientific, technical, and medical information products and services, on its acquisition of the business assets of Ariadne Genomics, a provider of pathway analysis tools and semantic technologies for life science researchers. The acquisition of Ariadne will serve to broaden Elsevier’s current portfolio of chemistry, pre-clinical and clinical workflow solutions offered to science and health professionals worldwide.
The transaction was led by New York M&A partner, Alan Zoccolillo, and included associates Alexandra Popoff and Jessie Cardinale; and Employee Benefits Partner, Pia Flanagan. The New York team was supported by a group of attorneys in the firm’s Moscow office including partners Alexey Frolov, Konstantine Kouzine, Margarita Divina and Igor Makarov.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals and close to 20,000 book titles. Elsevier’s online solutions enhance the productivity of science and health professionals and help research and health care institutions deliver better outcomes more cost-effectively. A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).